Processes of corporate growth in the evolution of an innovation-driven industry. The case of pharmaceuticals
The work studies the processes of growth of the world top 150 pharmaceutical firms, on the grounds of an original database which allows also disaggregate analysis at the level of single therapeutical classes and chemical entities.Our findings show that the industry -whose long-term evolution is driven by innovation , imitation and permanent creation of new markets - displays (i) 'fat tails' in the distribution of growth shocks , present at all levels of aggregation, with (relatively rare) big "spurs of growth";(ii) a significant autocorrelation of growth rates ,(iii) a fall of variance of growth rates with size, entirely dependent on corporate diversification patterns, in turn plausibly shaped by the "competence scope" of each firm, (iv) different "lifecycles" of diverse types of products, (v) persistent forms of heterogeneity across firms in terms of innovative output which however do not seem to affect comparative growth performances.
|Date of creation:||08 Dec 2000|
|Date of revision:|
|Contact details of provider:|| Postal: |
Web page: http://www.lem.sssup.it/
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:ssa:lemwps:2000/05. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ()
If references are entirely missing, you can add them using this form.